BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37131253)

  • 21. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
    Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
    Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The diagnostic significance of cerebrospinal fluid cytology and circulating tumor DNA in meningeal carcinomatosis.
    Di WY; Chen YN; Cai Y; Geng Q; Tan YL; Li CH; Wang YN; Shang YH; Fang C; Cheng SJ
    Front Neurol; 2023; 14():1076310. PubMed ID: 36937524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the cerebrospinal fluid ctDNA detection by next-generation sequencing in the diagnosis of meningeal Carcinomatosis.
    Zhao Y; He JY; Zou YL; Guo XS; Cui JZ; Guo L; Bu H
    BMC Neurol; 2019 Dec; 19(1):331. PubMed ID: 31856745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of mutation profiles and tumor mutation burden of cerebrospinal fluid circulating DNA by a cancer genomic panel sequencing in glioma patients.
    Guo W; Jin L; Liang J; Lin G; Zheng J; Zhou D; Zhan S; Sun H; Jiang X
    Clin Chim Acta; 2022 Sep; 534():81-92. PubMed ID: 35810802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease.
    Ballester LY; Glitza Oliva IC; Douse DY; Chen MM; Lan C; Haydu LE; Huse JT; Roy-Chowdhuri S; Luthra R; Wistuba II; Davies MA
    J Neuropathol Exp Neurol; 2018 Jul; 77(7):628-635. PubMed ID: 29873738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical Value of Cerebrospinal Fluid ctDNA in Patients 
with Non-small Cell Lung Cancer Meningeal Metastasis].
    Zhang K; Dai Z; Liu S; Li D; Yang D; Cui S
    Zhongguo Fei Ai Za Zhi; 2020 Dec; 23(12):1039-1048. PubMed ID: 33357310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC.
    Wu J; Liu Z; Huang T; Wang Y; Song MM; Song T; Long G; Zhang X; Li X; Zhang L
    Mol Oncol; 2023 May; 17(5):810-824. PubMed ID: 36495130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of intrapatient heterogeneity of circulating tumor cells at the single-cell level in the cerebrospinal fluid of a patient with metastatic gastric cancer.
    Cho JH; Sim MH; Kim SY; Kim K; Lee T; Lee J; Kang WK; Kim ST
    J Cancer Res Ther; 2021; 17(4):1047-1051. PubMed ID: 34528562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases.
    Angus L; Deger T; Jager A; Martens JWM; de Weerd V; van Heuvel I; van den Bent MJ; Sillevis Smitt PAE; Kros JM; Bindels EMJ; Heitzer E; Sleijfer S; Jongen JLM; Wilting SM
    Clin Cancer Res; 2021 May; 27(10):2798-2806. PubMed ID: 33514525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of circulating tumor DNA in cerebrospinal fluid by whole exome sequencing to detect genomic alterations of glioblastoma.
    Duan H; Hu JL; Chen ZH; Li JH; He ZQ; Wang ZN; Zhang GH; Guo XY; Liang L; Mou YG
    Chin Med J (Engl); 2020 Jun; 133(12):1415-1421. PubMed ID: 32558704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.
    De Mattos-Arruda L; Mayor R; Ng CKY; Weigelt B; Martínez-Ricarte F; Torrejon D; Oliveira M; Arias A; Raventos C; Tang J; Guerini-Rocco E; Martínez-Sáez E; Lois S; Marín O; de la Cruz X; Piscuoglio S; Towers R; Vivancos A; Peg V; Ramon y Cajal S; Carles J; Rodon J; González-Cao M; Tabernero J; Felip E; Sahuquillo J; Berger MF; Cortes J; Reis-Filho JS; Seoane J
    Nat Commun; 2015 Nov; 6():8839. PubMed ID: 26554728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer.
    Nevel KS; DiStefano N; Lin X; Skakodub A; Ogilvie SQ; Reiner AS; Pentsova E; Boire A
    Neuro Oncol; 2020 May; 22(5):675-683. PubMed ID: 32352148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA.
    Xi W; Zhou C; Xu F; Sun D; Wang S; Chen Y; Ji J; Ma T; Wu J; Shangguan C; Zhu Z; Zhang J
    J Transl Med; 2022 Aug; 20(1):365. PubMed ID: 35962408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unique genomic alterations of cerebrospinal fluid cell-free DNA are critical for targeted therapy of non-small cell lung cancer with leptomeningeal metastasis.
    Wang Y; Jiang F; Zhang Y; Li M; Li Y; Li H; Zhao Q; Shi M; Yu Y; Shao YW; Cai H; Miao L; Xia H
    Genomics; 2021 Nov; ():. PubMed ID: 34793951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unique Genomic Alterations of Cerebrospinal Fluid Cell-Free DNA Are Critical for Targeted Therapy of Non-Small Cell Lung Cancer With Leptomeningeal Metastasis.
    Wang Y; Jiang F; Xia R; Li M; Yao C; Li Y; Li H; Zhao Q; Shi M; Yu Y; Shao YW; Zhou G; Xia H; Miao L; Cai H
    Front Oncol; 2021; 11():701171. PubMed ID: 34671549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis.
    Chiang CL; Lee CC; Huang HC; Wu CH; Yeh YC; Shen CI; Luo YH; Shiao TH; Chang HJ; Huang YT; Chen YM; Chou TY; Chiu CH
    Target Oncol; 2021 Mar; 16(2):207-214. PubMed ID: 33566300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC.
    Zheng MM; Li YS; Tu HY; Jiang BY; Yang JJ; Zhou Q; Xu CR; Yang XR; Wu YL
    J Thorac Oncol; 2021 Feb; 16(2):250-258. PubMed ID: 33122107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a prospective cohort study.
    Li M; Hou X; Zheng L; Ma Y; Li D; Lv Y; Chen J; Zheng W; Shao Y; Mou Y; Chen L
    ESMO Open; 2022 Feb; 7(1):100305. PubMed ID: 34922300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis.
    Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):5-14. PubMed ID: 36318332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.